Clin2
NCT06267183Possibly a fitRecruiting

Safety study of a new drug in healthy volunteers

Idiopathic Pulmonary Fibrosis

Part of Lungs & breathing clinical trials.

This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
53 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You must be a healthy adult between 18 and 65 years old (implied by Chinese Healthy Adult Volunteers).
  • Your weight must be at least 50 kg if male, or 45 kg if female, with a body mass index (BMI) between 19 and 26.
  • You cannot have a history of serious drug allergies, drug abuse, or heavy smoking.
  • You must not have any significant medical conditions or take other medications that could interfere with the study.
  • You agree to use reliable birth control during and for a period after the trial.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06482190Recruiting· Phase 1
Safety study of an inhaled drug in healthy adults

This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.

Geelong, Victoria
NCT07682337Not yet recruiting· Phase 1
Testing a new drug in healthy men

This trial is testing a new drug called SCB0020160 in healthy adult men to see how safe it is and how the body processes it. You take the drug by mouth once or several times.

Adelaide, South Australia
NCT07407543Recruiting· Phase 1
Study of SRN001 in healthy Korean and Caucasian men

This trial tests a new drug called SRN001 in healthy men to see how safe it is and how the body processes it. It may help find the right dose for future studies.

Seoul
NCT07600021Not yet recruiting· Phase 2
Testing SYH2059 tablets for idiopathic pulmonary fibrosis

This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.

NCT06747923Recruiting· Phase 2
SB17170 for Idiopathic Pulmonary Fibrosis (IPF)

This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.

Goyang
NCT07469085Recruiting· Phase 1
Safety study of SV003 in healthy volunteers

This trial tests a new medication called SV003 in healthy people to see if it's safe and how the body processes it. You may be able to join if you are in good health and meet certain weight and lifestyle requirements.

Shanghai

Hear when a new Idiopathic Pulmonary Fibrosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.